Sharlene Gill, MD, MPH, FACP, FRCPC, highlights significant research data on developments in the treatment of GIST and NETs.
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Dr Riechelmann shares data on young adults with NETs presenting a high rate of pathogenic or likely pathogenic germline variants in cancer-predisposing genes, which were presented at the virtual ESMO…
Patients given ripretinib for advanced GIST in the INVICTUS trial had improved PFS and OS, according to data presented at the virtual ESMO World Congress on GI Cancer.
No significant OS disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for CRC peritoneal metastases, according to long-term survival data.
Despite having high-risk features, most patients receiving first-line encorafenib plus binimetinib and cetuximab for BRAFV600E+ mCRC in the ANCHOR CRC trial had tumor regression.
Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Study findings suggest a regimen comprising nivolumab and radical surgery after chemoradiotherapy as a candidate therapy for locally advanced, MSS and MSI-H CRC.
Stay in the know.
OncNet Newsletter